Ty -jour t1-慢性血栓栓塞性肺动脉高压jf -Eurom呼吸杂志JO -EUR RESSIR J SP -595 LP -600 do -10.1183/09031936.04.00044.00020004 VL -23 IS -4 AU -4 AU -4 AU -4 au -4 au -bresser，p. au -bresser，Fedullo，P.F。Au -Auger，W.R。Au -Channick，R.N。Au -Robbins，I.M。Au -Kerr，K.M。Au -Jamieson，S.W。Au -Rubin，L.J。Y1-2004/04/01 Ur -http：//www.qdcxjkg.com/content/23/4/4/595.abstract N2-慢性血栓性肺泡肺高血压（CTEPH）中的病理生理发现（CTEPH）已经建议小血管动脉炎可能有助于这些患者观察到的血流动力学障碍。据推测，升高的血管耐药性元素可能对连续静脉内propoprostenol疗法有反应。回顾性地，在九名CTEPH患者中评估了对连续静脉内propoprostenol的临床和血液动力学反应，这些患者随后接受了肺血栓性血管内切除术（PTE）。在开始前寄生醇植物之前确定心肺血液动力学，而在pTE之前，PTE和PTE之后。 Six patients, treated for 2–26 months prior to PTE, experienced either clinical stability or improvement that was associated with a mean reduction in pulmonary vascular resistance (PVR) of 28% (median 33%, range 0–46%). Three patients, treated for 3–9 months, experienced clinical deterioration during epoprostenol administration, with a significant increase in PVR in two patients. Subsequent PTE resulted in a highly significant improvement of cardiac index, mean pulmonary artery pressure and total pulmonary resistance. To conclude, selected patients with chronic thromboembolic pulmonary hypertension may benefit clinically and haemodynamically from continuous intravenous epoprostenol treatment prior to pulmonary thromboendarterectomy. Factors predictive of a beneficial response, and whether this intervention influences either morbidity or mortality associated with pulmonary thromboendarterectomy, remain to be established. I.M. Robbins was supported by NIH grant RR 15534. ER -